Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
News|Articles|July 17, 2026

3D iPSC Expansion as Aggregates within a Distek BIOne Single-Use Bioreactor with a Microsparger Used for Media Exchange

Author(s)Distek, Inc

Discover how scalable 3D suspension culture can improve human induced pluripotent stem cell (iPSC) expansion compared to traditional 2D methods. This poster demonstrates process development within a BIOne 2L single-use bioreactor, highlighting aggregate size control, cell viability, expansion performance, and cost efficiency while achieving a 60-fold expansion over five days using Defined Bioscience HiDef® S8™ medium.


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.